![\"New](\"https:\/\/images.newscientist.com\/wp-content\/uploads\/2024\/06\/12102232\/SEI_2081760211.jpg\")
<\/div>ADDICTIVE STOCK CREATIVES\/Alamy; AdoBe stock<\/p>\n<\/div>\n<\/figcaption><\/figure>\n<\/p>\n
Kathy Schwartz\u00a0was 10 years free from alcohol, cigarettes and opiates but every day it was painful to control her cravings. \u201cThey were always in the background,\u201d she says. In June last year, however, this noise fell silent.<\/p>\n
Prescribed the weight-loss drug semaglutide, she not only lost nearly 30 kilograms over 10 months, but also her desire to reach for a drink or take some pills. \u201cI do not crave, which I didn\u2019t think would be a side effect,\u201d says Schwartz. Remarkably, the depression<\/a> and anxiety<\/a> that would previously come over her in waves also calmed down.<\/p>\n Schwartz isn\u2019t alone in this experience. New research is revealing the surprising brain and mental health benefits of semaglutide drugs such as Ozempic and Wegovy, and other related diabetes and weight-loss drugs that mimic a gut hormone released after eating.<\/p>\n It is early days, but there are hints that these drugs could be repurposed to treat depression, anxiety, addiction and even certain eating disorders \u2013 as well as neurological conditions such as Parkinson\u2019s disease and Alzheimer\u2019s. What\u2019s more, it seems that these effects aren\u2019t just mediated via weight loss, but through direct action on the brain.<\/p>\n The story of drugs like Ozempic starts back in the 1970s and 1980s when researchers discovered that a gut hormone called glucagon-like peptide-1<\/a> (GLP-1) could stimulate insulin production when injected into rodents in the lab. More surprisingly, these animals started eating less and losing weight. We now know that the hormone leads to an increased feeling of fullness.<\/p>\n Today, drugs that mimic\u2026<\/p>\n<\/p><\/div>\nSemaglutide and more<\/h2>\n